Background: Cell-to-cell variability in populations has been widely observed in mammalian cells. This heterogeneity can result from random stochastic events or can be deliberately maintained through regulatory processes. In the latter case, heterogeneity should confer a selective advantage that benefits the entire population. Results: Using multicolor flow cytometry, we have uncovered robust heterogeneity in phosphoinositide 3-kinase (PI3K) activity in MCF10A cell populations, which had been previously masked by techniques that only measure population averages. We show that AKT activity is bimodal in response to EGF stimulation and correlates with PI3K protein level, such that only cells with high PI3K protein can activate AKT. We further show that heterogeneity in PI3K protein levels is invariably maintained in cell populations through a degradation/resynthesis cycle that can be regulated by cell density. Conclusions: Given that the PI3K pathway is one of the most frequently upregulated pathways in cancer, we propose that heterogeneity in PI3K activity is beneficial to normal tissues by restricting PI3K activation to only a subset of cells. This may serve to protect the population as a whole from overactivating the pathway, which can lead to cellular senescence or cancer. Consistent with this, we show that oncogenic mutations in p110a (H1047R and E545K) partially evade this negative regulation, resulting in increased AKT activity in the population.
Introduction
Among the thousands of proteins expressed in a single cell at any one time, it is inevitable that even genetically identical cells will have variable expression of certain proteins. This cell-tocell heterogeneity can have profound effects on the phenotype of a population. In bacteria and yeast, a heterogeneous population has a better chance of surviving in fluctuating environments [1] [2] [3] . In cancer cells, variable protein expression results in nonuniform responses to anticancer agents and only ''fractional'' killing, which is beneficial to the tumor but detrimental to the patient [4] [5] [6] [7] .
Population heterogeneity can be the result of genetic and nongenetic variability [8] . Nongenetic sources of heterogeneity are of particular interest because they are not fixed in the population by heritable transmission. Rather, these sources can be stochastic in nature, such as random fluctuations in transcription or translation, or they can be regulated, such as through feedback mechanisms, so that variability is deliberately maintained. Flow cytometry allows us to measure protein concentrations in single cells within large populations, which has proved useful in differentiating between stochastic and regulated sources of variation. Variable protein levels caused by stochastic events are usually rare and slightly increase the coefficient of variance of an otherwise log-normal concentration distribution [9] . Regulated variance usually deviates from tight log-normal distributions and in the most extreme cases might display bimodality [10] . Additionally, variance in the expression level of these proteins tends to correlate with variance in functionally related proteins [9] .
We demonstrate cell-to-cell variability in phosphoinositide 3-kinase (PI3K) pathway activation in mammary epithelial cells that is indeed bimodal and also correlates with multiple proteins in the pathway. This implies that heterogeneous PI3K activation in cell populations is maintained by a regulated process and likely confers a selective advantage. The PI3K pathway regulates numerous critical cellular functions such as proliferation, growth, and survival and is one of the most frequently altered pathways in human cancer [11] . Tumor cells have evolved numerous ways of overactivating this pathway to induce tumorigenesis, such as amplifications or mutations in upstream receptor tyrosine kinases (RTK), mutations or deletion of the negative regulator PTEN, somatic mutations in PI3K itself, and combinations of the above [12] [13] [14] . In this view, we propose that cell-to-cell variability in PI3K activity serves as a mechanism to keep overall PI3K activity limited in normal tissues to avoid hyperactivity that may lead to cancer.
Results

AKT Activation in MCF10A Populations Is Heterogeneous and Exhibits a Bimodal Distribution
To assess cell-to-cell variability in PI3K pathway activation, we acutely stimulated serum-and growth factor-starved MCF10A cells with EGF and measured AKT activity in single cells by flow cytometry. As expected, in the absence of EGF or with pretreatment with the PI3K inhibitor wortmannin, cells exhibited a log-normal distribution in the pAKT-negative gate ( Figure 1A ). Following treatment with saturating amounts of EGF, we observed striking heterogeneity in AKT activation characterized by the bimodal distribution of cells into the pAKT-negative (w70%) or pAKT-positive (w30%) gates ( Figure 1A ). The percentage of cells in the positive gate was maximal at 5-10 min and decreased over time. We found that the bimodality was not due to differential EGFR activation or total AKT protein abundance, both of which exhibit log-normal distributions and show weak correlation with pAKT status (see Figures S1A and S1B available online). Bimodality was also observed following insulin stimulation, suggesting that this is a general, rather than ligand-specific, effect on PI3K activation ( Figure S1C ). We also observed robust bimodal activation of AKT in another nontransformed human mammary epithelial cell line (HMEC; Figure S1E ).
As reported in the literature, cell populations expressing the oncogenic H1047R PIK3CA mutation have higher AKT activity [15] [16] [17] . The enzyme encoded by this mutant form of PIK3CA has been shown to have higher specific activity than that encoded by wild-type PIK3CA [15, 16] . To explore the possibility that this mutation shifts cells uniformly to the pAKT-positive state, we analyzed MCF10A cells stably expressing this mutant form of p110a by flow cytometry. We observed that even in the presence of oncogenic p110a, cells still segregate into a bimodal distribution and retain a substantial population of nonresponders. The H1047R mutation in MCF10A cells thus achieves higher average pAKT levels by shifting more cells into the pAKT-positive state ( Figure 1A ). This implies that the mechanism that maintains heterogeneity in cell populations is both robust and not eliminated by expression of a mutant form of PI3K with constitutively high specific activity.
Finally, we wanted to ensure that heterogeneous AKT activation is preserved in more physiological settings. Debnath et al. have previously observed sporadic pAKT staining in MCF10A 3D acinar structures, which is important for proper lumen formation [18, 19] . To see whether this heterogeneous AKT activation was observed in vivo, we analyzed spontaneously arising tumors from MMTV-Cre; BRCA1 flox/flox ; p53 +/2 mice and indeed observed heterogeneity in pAKT positivity ( Figure 1B) . (A) Cells were starved and acutely stimulated with 5 nM EGF for 5 min with or without pretreatment with 100 nM wortmannin. Cells were then harvested and stained with anti-pAKT S473 antibody and analyzed by flow cytometry. Unstimulated and wortmannin-treated cells are pAKT negative (P6). EGF stimulation activates w30% of cells and shifts them into the pAKT-positive gate (P7). Cells stably expressing the oncogenic H1047R p110a mutant exhibit basal AKT activity in the unstimulated state (as previously reported), and EGF stimulation shifts more cells into the pAKT-positive gate (P7) and also increases the amplitude of pAKT signal (P8). p110a Protein Level Is Variable in Single Cells and Determines AKT Activity Given that the bimodal AKT activation could not be explained by bimodal distribution of activated EGFR or total AKT protein, we next looked for variability in PI3K protein abundance. There are no p110a antibodies amenable for flow cytometry, but pAKT bimodality was maintained in MCF10A cells stably expressing HA-tagged p110a. We thus utilized anti-HA antibodies to monitor levels of p110a. Using single-cell analysis, we found that p110a protein levels, like pAKT, exhibit bimodality in cell populations ( Figure 1C ). p110a protein level also positively correlated with pAKT status (R 2 = 0.68), indicating that only cells with high levels of p110a can activate AKT. Cells with medium levels of p110a have intermediate levels of AKT activity, suggesting that these cells may be transitioning dynamically between the two dominant modes ( Figure 1C ). Subpopulations in these varying states can also be visualized by immunofluorescence ( Figure 1D ).
The p85a-p110a heterodimer is a very stable complex that does not readily dissociate, and it is thus thought that p110a levels generally correlate with p85a levels [20, 21] . We monitored the distribution of endogenous p85a in MCF10A cells, and we show that levels of endogenous p85a mirror that of HA-tagged p110a in single cells ( Figure S1D ). This correlation indicates that the heterogeneity we observe is not an artifact of exogenously expressed p110a and confirms that high levels of the entire functional holoenzyme are required for AKT activation, as expected.
p110a Protein Levels Are Dynamic within Single Cells
In agreement with previous studies [22] [23] [24] , total PI3K levels do not appear to change upon growth factor stimulation, as measured by western blot (Figure 2A) . To test the possibility that p110a protein levels are dynamic on the subpopulation level, we measured p110a levels in pAKT-positive and pAKTnegative subpopulations over a time course of EGF stimulation by single-cell analysis. Surprisingly, we observed dynamic changes in p110a protein in pAKT-positive cells. This minor subgroup of cells has the highest levels of p110a (and the highest levels of pAKT) and undergoes a precipitous drop in p110a protein at 10 min after EGF stimulation, when AKT activity is maximal ( Figure 2B ). Over the next 4 hr, this population gradually recovers p110a levels ( Figure 2B ). In contrast, the major subgroup of cells with low levels of pAKT and low p110a does not show a significant decline in p110a (or activation of AKT) during the time course of EGF stimulation. We attempted to verify these results with live cell imaging of fluorescently tagged p110a, but the size of the fluorescent protein-p110 fusion prohibited efficient transfection and expression. However, our observed changes in p110a levels also correlate with a striking change in the proportion of cells in the p110a high , p110a medium , and p110a low subpopulations over the time course of EGF stimulation. After 10 min of EGF stimulation, there is a major drop in the proportion of cells in the p110a high state and an increase in the proportion of cells in the p110a medium state ( Figure 2C ). Over the next 4 hr, the populations recover to the original distribution ( Figure 2C ). These data indicate that there is a significant decrease in p110a levels in a subpopulation of cells characterized by high pAKT and high p110a. The failure to detect this acute change in p110a by western blot can be explained by the fact that this population represents only a minor fraction of total cells, whereas the protein in a western blot is dominated by a major fraction of cells (70%-80%) that fail to activate the PI3K/AKT pathway and maintain static p110a levels. Endogenous p85a levels exhibit nearly identical kinetics to p110a, indicating that the entire holoenzyme is dynamically regulated to modulate AKT activity ( Figure S2 ).
We also plotted the time course of EGF-stimulated AKT phosphorylation in the subpopulations of cells that had high, medium, or low levels of p110a ( Figure 2D ). The subset of cells with the highest level of p110a had not only the highest pAKT signal amplitude but also the longest pAKT signal duration. However, the overall population response was dominated by the major subset of cells that had minimal AKT phosphorylation.
Dynamic Changes in p110a Protein Levels Are Regulated by a Degradation/Resynthesis Cycle We next sought to understand the mechanism by which p110a levels were modulated. In these cells, HA-p110a expression is driven by the CMV promoter, suggesting that variability in p110a expression is posttranscriptionally regulated. To test whether the drop in p110a levels in actively signaling cells was due to proteosome-mediated degradation, we treated cells with MG132 and observed an increase in p110a protein on the population level ( Figure 3A) . On the subpopulation level, MG132 treatment resulted in the accumulation of cells in the p110a medium state and a loss of cells from the p110a low state ( Figure 3B ). This suggests that proteosome-mediated degradation of p110a transitions cells from the p110a high/medium state to the p110a low state, thereby negatively regulating AKT activity. Short-term treatment of cells with MG132 prior to acute EGF stimulation partially rescues the drop in p110 levels in pAKT high cells and prevents the shift of cells from the p110a high to p110a medium state ( Figures S3A and S3B ). To show that p110a can be resynthesized and thus transition cells from the p110a low to the p110a medium/high state, we treated cells with cyclohexamide (CHX). On the population level, we observed an overall decrease in p110a protein with CHX treatment ( Figure 3A) . On the subpopulation level, we observed an accumulation of cells in the p110a low state with concomitant loss of cells from the p110a medium and p110a high states ( Figure 3B ). These data show that p110a resynthesis is responsible for shifting cells from the p110a low state to the p110a high state, thereby generating cells competent to activate AKT.
Our results thus far suggest a model whereby p110a levels in single cells oscillate via a degradation/resynthesis cycle, which transitions cells through phases of high p110a (competent to activate the pathway) and low p110a (incompetent to activate the pathway). Large populations contain cells in various stages of this cycle, thus accounting for the vast heterogeneity we observe ( Figure 3C ). Though many extrinsic factors are likely to influence the duration and progression of this cycle, we found no correlation between p110a or pAKT status with cell cycle, as assessed by DNA content, or with cell size or granularity (Table S1 and Figure S3C ).
Hot Spot PIK3CA Mutations Confer Stabilization of the p110a high State Escaping this negative regulation of AKT may be particularly important in cancer cells, given that H1047R-expressing MCF10A cells and several tumor-derived breast cancer cell lines can activate AKT in a greater proportion of cells compared to nontransformed cell lines ( Figure 1A ; Figure S1E ). To test whether this was due to the ability to stabilize the p110a high state, we measured the level of p110a in MCF10A cells stably expressing exogenous HA-tagged wild-type, H1047R mutant, or E545K mutant p110a.
Both mutant forms of p110a were expressed at higher levels than wild-type p110a ( Figure 4A ), which was due to the maintenance of more cells in the p110a high state and fewer cells in the p110a low state ( Figures 4B, 4C , and 4H). To ensure that these differences were not due to variability in retroviral infection efficiency, we tested multiple batches of cell lines, and all lines were grown under selection for several generations before use in experiments.
We next sought to determine whether the mutant forms of p110a were stabilizing the p110a high state by resisting degradation. We monitored the degradation kinetics of the mutant cell lines as we did in Figure 2B . Though both mutant cell lines underwent rapid p110a degradation following EGF stimulation, the E545K mutant displayed more muted degradation (though this was, in part, due to higher basal expression), and both mutants exhibited considerable variability between experiments compared to wild-type ( Figure 4D ). Additionally, MG132 treatment of asynchronously growing mutant cells did not result in an increase in overall p110a levels, as observed in the wild-type line ( Figure 4E ). These results suggest that the H1047R and E545K mutations confer resistance to proteosome-mediated degradation under exponential growth conditions that may be distinct from the acute degradation that occurs following EGF stimulation of starved cells. Notably, all cell lines responded similarly upon CHX treatment, ruling out the possibility that mutant p110a is preferentially synthesized (Figure 4E ).
To determine whether stabilization of PI3K contributes to the oncogenic potential of the mutants, we compared overall AKT activity to total p110a levels in mutant and wild-type cells. During exponential growth, H1047R-and E545K-expressing cells had 3.9-fold and 2.4-fold, respectively, more total AKT activity than those expressing wild-type PIK3CA, though the corresponding p110a levels were only 2.0-fold and 1.7-fold higher ( Figures 4A, 4F, and 4G ). Given that these mutant forms of p110a are more enzymatically active [15, 16] , we predict that the combination of more cells in the p110a
high state and higher enzymatic activity cooperate to induce oncogenic levels of AKT activity.
p110a
high Cells Initiate Colony Formation We next investigated whether p110a high cells had unique functional roles. We seeded single cells from wild-type, H1047R, and E545K parental cell lines and generated clonal cell lines. Remarkably, nearly 100% of the clones that emerged exhibited a bimodal profile that was the reverse of the parental population. At early passage, the majority of cells were in the p110a high state, and a minority was in the p110a low state, with corresponding changes in pAKT ( Figure 5A and Table  S2 ). These results suggest that only p110a high cells were capable of forming colonies, at least partially by maintaining high AKT activity. This is likely important for overcoming low cell-density-related and replicative stresses, because we observed that cell lines overexpressing p110a, either wildtype or mutant, survived many more serial passages than clones with only endogenous levels of p110a ( Figure 5B and Table S2 ).
If enrichment for p110a high cells is important in the early stages of colony formation, we next wanted to test whether the clones reverted back to the parental distribution once the population established steady exponential growth. We compared p110a levels at early and late passages and indeed saw reversion to the parental distribution with the majority of cells in the p110a low state in late passages ( Figure 5C ). We carefully monitored the rate of reversion by measuring p110a levels in sequential passages and observed a gradual decrease in the percentage of cells with high p110a in nearly all clones by passage 8 ( Figure 5D ). This suggests that p110a high cells are critical for colony formation and early clonal expansion, but heterogeneous populations of predominantly p110a low cells facilitate exponential growth. To ensure that there was no genetic component to these effects, we established a second generation of clones from primary clonal populations and observed the same trends (Table S2) . (D) Cells expressing wild-type or mutant p110a were treated as described in Figure 2B . Total levels of p110a in the whole population did not change over time (solid lines), though the mutant cells retained higher average p110a levels than the wild-type cells. In the pAKT high subpopulations (dashed lines), the mutants followed similar dynamic changes in p110a levels as described for wild-type, though with much greater variability. (E) Asynchronously growing wild-type and mutant lines were treated with CHX or MG132 as described in Figure 3A . All cell lines showed a decrease in p110a levels following treatment with CHX. However, the mutant lines were less sensitive to the MG132 treatment than the wild-type line. (F) Average AKT activity in asynchronously growing wild-type and mutant cell populations was measured by flow cytometry. The H1047R and E545K mutant lines exhibited 3.9-fold and 2.4-fold increases, respectively, in total pAKT level compared to wild-type. Data are from at least three independent experiments, and error bars represent standard error of the mean. (G) Wild-type and mutant cells were analyzed by immunofluorescence, as described in Figure 1 . Additionally, reverted clonal cell lines exhibited similar p110a kinetics after EGF stimulation to parental populations ( Figures  S4A-S4C) .
Interestingly, at passage 3, both H1047R-and E545K-derived clones harbored higher percentages of p110a high cells compared to wild-type clones and reverted to the parental distribution at a slower rate than wild-type ( Figure 5D ). This is consistent with our previous observation that mutant p110a can stabilize the p110a high state (Figure 4 ; Figure S4D ). (C) Analyzed on the subpopulation level, the decrease in p110a can be attributed specifically to a decrease in the p110a high subpopulation and an accumulation of the p110a low subpopulation. (D) To verify these results, we grew cells to w50% confluency and assessed p110a levels by immunofluorescence (left). Cells with few or no cell-cell contacts (white circles) stained brightly for HAp110a, whereas cell clusters with many cell-cell contacts (orange boxes) displayed heterogeneity in HA-p110a staining intensity. The number of cell-cell contacts was counted for 875 individual cells and compared to their p110a status (right). p110a high cells were enriched for cells with 0-1 cell-cell contacts, and p110a low cells were enriched for cells with 2-4 cell-cell contacts.
Importantly, the few clones that failed to undergo a reversion to the parental distribution were predominantly mutant clones with very high percentages of p110a high cells ( Figure 5D ). These clones ceased to proliferate after passage 3-4 and exhibited a spindly morphology and senescence-associated b-galactosidase activity ( Figure 5E ). We find these data to be consistent with a model in which reversion to a bimodal distribution of primarily p110a low cells is required to maintain exponential growth and in which failure to revert results in oncogene-induced senescence.
Establishing Cell-Cell Contacts Stabilizes the p110a low State If low cell density contributed to the induction of high p110a during colony formation, we wanted to explore the possibility that increasing cell-cell contacts induces the p110a low state. We measured p110a levels of exponentially growing populations every 24 hr and found that p110a and pAKT levels steadily decreased as cell density increased ( Figures 6A and 6B) . The decrease in total p110a can be attributed specifically to a drop in the proportion of p110a high cells and an accumulation of p110a low cells (Figure 6C) . This is also apparent in small cell clusters, where p110a levels are heterogeneous compared to lone cells that tend to be p110a high ( Figure 6D ). Under these low-density growth conditions, the p110a high population is enriched for cells with 0-1 cell-cell contacts, whereas the p110a low population is enriched for cells with 2-4 cell-cell contacts ( Figure 6D ).
Thus, cell-cell contacts may modulate p110a levels in order to establish contact inhibition and/or confluence arrest.
We next considered the possibility that cells with high AKT activity are enriched at the unencumbered edges of tumors, which are less confluence inhibited and highly proliferative. These ''pushing margins'' are a distinct, though molecularly uncharacterized, feature of mutant BRCA1-driven tumors [25, 26] . We thus stained mammary tumors arising from MMTV-Cre; BRCA1 flox/flox ; p53 +/2 mice for pAKT S473. We detected heterogeneous pAKT positivity throughout the tumor ( Figure S5A ) and an enrichment of pAKT-positive cells along pushing margins (Figures S5B-S5F ) and in the lumens of ductal hyperplasias (Figures S5G and S5H) . Both of these regions represent areas with fewer cell-cell contacts, supporting our hypothesis that low cell density enhances the pAKTpositive state. However, given that no antibodies against p110a or p85a are amenable to immunohistochemical staining, we cannot confirm that this high AKT activity correlates with high PI3K protein.
Discussion
Nongenetic cell-to-cell variability has been observed in numerous cellular systems and can lead to distinct cellular fates. The most classic example is Ferrell and Machleder's study of Xenopus oocyte maturation, which shows that variability in mitogen-activated protein kinase phosphorylation leads to either a G2 or metaphase arrest [27] . Similarly, high or low levels of Nanog determine the potential of embryonic stem cells to terminally differentiate [10, 28] , and high or low levels of Sca-1 dictate the proclivity for hemapotoietic progenitor cells to commit to the erythroid or the myeloid lineage [29] . Another cellular fate that is determined by variable protein expression is the drug-tolerant/drug-sensitive state. In certain cell lines, gefitinib resistance can be conferred by high IGF-1R signaling and high KDM5A expression [7] , and camptothecin resistance can be conferred by high DDX5 or RFC1 expression [4] . Our study now shows that heterogeneity in signal transduction is another meaningful source of cell-tocell variability that does not result in distinct cell fates, but rather influences the transient behavior of the entire population.
We show that a bimodal distribution of AKT activation is an invariable characteristic of exponentially growing MCF10A cells. We propose that limiting AKT activity to only 20%-30% of cells in a population serves two related purposes: (1) to prevent senescence, and (2) to maintain suboncogenic levels of PI3K activity in large populations.
Our data show that clonal populations that are unable to revert to the parental distribution of primarily p110a low cells undergo cellular senescence. In these clones, p110a high ; pAKT high cells comprise 80%-90% of the population immediately prior to senescence, indicating that such high PI3K activity is not sustainable. These results are consistent with models of p53-dependent cellular senescence associated with the loss of two negative regulators of PI3K, PTEN and inositol polyphosphate 4-phosphatase type II (INPP4B) [30, 31] . Given that MCF10A cells are p53 replete, it is possible that overaccumulation of p110a high cells induces senescence by the same mechanism.
A second selective advantage of maintaining variability in PI3K activity may be to maintain suboncogenic levels of PI3K activity in large populations such as tissues and organs. Given that overactivation of this pathway is one of the most frequent events in cancer, permitting PI3K activation in only a fraction of cells within a population may be a simple mechanism to limit overall PI3K activity. However, we show that variability is not completely overcome in populations expressing oncogenic forms of p110a or in epithelial tumor sections, which may have important implications on tumor susceptibility to PI3K inhibitors.
Assuming that only tumor cells with high levels of pathway activation are likely to die in response to acute inhibition of PI3K, then tumors with mosaic patterns of pathway activation (e.g., as judged by pAKT staining) will exhibit only a partial response to a PI3K (or AKT) inhibitor. The mosaic pattern of pathway activation could be due to genetic variability or oscillation between high and low levels of PI3K expression (as seen in MCF10A cells). In the latter case, it may be possible to kill a larger fraction of the tumor cells by adjusting the therapy to ensure that the subset of cells that are protected from PI3K inhibitor therapy at the time of the initial dose become exposed to the inhibitor a second time as they cycle into a high PI3K pathway state. Thus, a detailed understanding of the pharmacokinetics of the drug is important in deciding the intensity and frequency of dosing. Although continuous high doses of PI3K inhibitors over several days or weeks might effectively kill all tumor cells as they cycle into the high activity state, dose-limiting toxicities might preclude such treatment. An alternative approach of using a very high single dose once a week could avoid toxicities associated with continuous dosing and result in 20%-30% tumor cell death at the first treatment, followed by a period in which another 20%-30% of the resistant tumor cells cycle into the high PI3K pathway state and die at the second treatment and so on.
Various preclinical studies using PI3K inhibitors may support this hypothesis. Once-daily oral administration of the Novartis pan-PI3K/mTOR inhibitor, NVP-BEZ235, to tumor-bearing mice results in delayed tumor growth but rarely tumor regression. pAKT is ablated in these tumors 1-2 hr after dosing but reemerges several hours later [32] [33] [34] . Similar results were observed using the Genentech class 1A PI3K inhibitor, GDC-0941 [35, 36] . Our data would suggest that cells that were PI3K low ;pAKT low during the initial dose escaped the toxic effects of the drug and cycled to the PI3K high ;pAKT high state several hours later when concentrations of the drug decreased. The possibility that PI3K inhibitors are selectively targeting the advancing edges or ''pushing margins'' of tumors is also consistent with fact that these tumors are not advancing, but rather are stabilizing.
As we emphasized throughout this study, variability in PI3K activity in cell populations is a regulated process. Though the mechanism regulating PI3K degradation and resynthesis is beyond the scope of this study, it is tempting to consider inhibition of resynthesis to dampen PI3K activity in all cells. Another alternative is to inhibit the E3 ligase that targets PI3K for degradation, which may overactivate the pathway in all cells and induce cellular senescence. This ''prosenescence'' approach has recently shown promise in a prostate cancer xenograft model where PTEN is pharmacologically inhibited [37] .
Experimental Procedures
Cell Lines and Cell Culture MCF10A cells were obtained from the American Type Culture Collection and cultured as described by Debnath et al. [38] . Stable MCF10A cell lines expressing HA-tagged wild-type or mutant (H1047R or E545K) bovine p110a were generated by retroviral infection as previously described [15] . Expression of wild-type and mutant PIK3CA cDNA was driven by the exogenous CMV promoter of the JP1520 retroviral vector (J. Pearlberg). Where indicated, cells were starved in growth media without horse serum, EGF, or insulin for w20 hr. Acute stimulation with growth factors was done by adding growth factor directly to the starvation medium.
Preparation of Cells for Flow Cytometry
A detailed description of how to prepare adherent cells for analysis by flow cytometry is provided in the Supplemental Experimental Procedures. Antibodies used for flow cytometry were: anti-HA.11-488 conjugate (Covance); anti-p-AKT S473 (D9E)-488/647 conjugates, anti-total AKT-647 conjugate, anti-pEGFR Y1068 (Cell Signaling); anti-p85a (Upstate Biotechnology); and various secondary Alexa Fluor dyes (Invitrogen). Data were analyzed with BD FACSDiva software (BD Biosciences), FlowJo software (Tree Star), and Cytobank [39] .
Generation of Clonal Populations
Parental pooled populations were passaged >9 times in selection media to normalize for infection efficiency. Parental cells were trypsinized, diluted, and plated at a density of 1 cell/well. Colony formation was monitored daily, and media were changed every 3 days. Once colonies grew to a sufficient size, they were trypsinized and replated (passage 1), and serially passaged thereafter.
Immunoassays
Detailed protocols for immunofluorescence, immunoblotting, and immunohistochemistry are provided in the Supplemental Experimental Procedures.
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